Skip to content

Evaluation of the efficacy of beverage containing plant-derived components on postprandial blood lipids elevation

Evaluation of the efficacy of beverage containing plant-derived components on postprandial blood lipids elevation - The effect of beverage containing plant-derived components on postprandial blood lipid concentrations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000046219
Enrollment
40
Registered
2022-01-10
Start date
2022-01-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Sponsors

KAGOME CO., LTD.
Lead Sponsor
HUMA R&amp
Collaborator
D CORP
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy adults (20 years or older) who do not get treatment or medication 2) Subjects who are normotriglyceridemia in previous medical check-ups 3) Subjects whose fasting blood triglyceride levels are not less than 30 mg/dL and less than 150 mg/dL in the screening test 4) Subjects who do not meet the key exclusion criteria 5) Subjects who are judged healthy by investigators

Exclusion criteria

Exclusion criteria: 1) Subjects who have food allergy to the test meals 2) Subjects who can not eat cream of corn soup within scheduled time 3) Subjects who can not get their blood sampled as scheduled 4) Subjects who have remarkable hypersensitivity to alcohol 5) Subjects who will get pregnant or breast-feed during the study period 6) Subjects who join other human studies 7) Subjects who are judged unsuitable for this study by investigators

Design outcomes

Primary

MeasureTime frame
Blood triglyceride levels, the peak value of blood triglyceride levels, delta blood triglyceride levels, delta Cmax (the peak value of delta blood triglyceride levels), IAUC (areas calculated based on the change of delta blood triglyceride levels)

Secondary

MeasureTime frame
Blood remnant like particles-cholesterol (RLP-C) levels, the peak value of blood RLP-C levels, delta blood RLP-C levels, delta Cmax (the peak value of delta blood RLP-C levels), IAUC (areas calculated based on the change of delta blood RLP-C levels)

Countries

Japan

Contacts

Public ContactHidemasa Toya

HUMA R&D CORP Clinical Development Department

toya@huma-rd.co.jp03-3431-1260

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026